Likarda, LLC
Likarda is a biotech company dedicated to transforming the delivery of cell therapies through innovative, customizable hydrogel-based platforms. Their mission is to increase the potency and efficacy of cell therapies by developing advanced encapsulation and delivery technologies, including Core Shell Spherification® (CSS), to protect, target, and enhance therapeutic outcomes. With a culture emphasizing diversity, inclusion, and scientific excellence, Likarda aims to provide sustainable solutions for treating chronic and fatal diseases in both human and animal health.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Hydrogel microbead encapsulation platform
A platform technology to encapsulate cells, cell clusters, peptides, antibodies, or scaffolds in tunable hydrogel microbeads enabling targeted local delivery, immune protection, and controlled release.
Hydrogel microbead encapsulation platform
A platform technology to encapsulate cells, cell clusters, peptides, antibodies, or scaffolds in tunable hydrogel microbeads enabling targeted local delivery, immune protection, and controlled release.
Services
Collaborative development of tailored hydrogel microbead formulations and encapsulation processes to target delivery, protect cells from immune attack, and tune release profiles.
Preclinical support including surgical induction in animal models and functional testing of encapsulated cell products to assess engraftment and therapeutic effect.
Analytical services to characterize hydrogel carriers and harmonize critical assays across cell therapy products (viability, function, release testing).
Process and cost optimization consulting, including analysis of cell expansion/differentiation inputs and design choices to improve manufacturability and reduce final product costs.
Collaborative development of tailored hydrogel microbead formulations and encapsulation processes to target delivery, protect cells from immune attack, and tune release profiles.
Preclinical support including surgical induction in animal models and functional testing of encapsulated cell products to assess engraftment and therapeutic effect.
Analytical services to characterize hydrogel carriers and harmonize critical assays across cell therapy products (viability, function, release testing).
Process and cost optimization consulting, including analysis of cell expansion/differentiation inputs and design choices to improve manufacturability and reduce final product costs.
Expertise Areas
- Cell therapy delivery system development
- Hydrogel formulation and crosslinking chemistry
- Microencapsulation and microbead manufacturing
- Preclinical evaluation of cell therapies
Key Technologies
- Core-shell hydrogel spherification
- Hydrogel microbeads for cell and biologic encapsulation
- Natural, synthetic, and hybrid hydrogel chemistries (e.g., HA, PEG, PVA)
- Chemical, photo-initiated, ionic, and thermal crosslinking
News & Updates
Kennedy Davis, a Kansas City University student intern, received the award for her research on cell therapy for knee osteoarthritis, supporting FDA development pathways and interdisciplinary research.
The publication demonstrates how CSS hydrogel encapsulation improves the performance of liver cell therapies and addresses major challenges in cell transplantation.
The partnership combines AI-powered protein manufacturing with advanced drug delivery technologies to accelerate biologic drug development.
Research shows that PVA hydrogel microencapsulation improves liver cell function over traditional alginate, supporting advanced cell therapies.
An overview of hydrogel-based delivery systems, their chemistry, crosslinking methods, and impact on cell therapy success.
Development of hydrogel microspheres for sustained delivery of stem cells and therapeutics in joint repair.
Kennedy Davis, a Kansas City University student intern, received the award for her research on cell therapy for knee osteoarthritis, supporting FDA development pathways and interdisciplinary research.
The publication demonstrates how CSS hydrogel encapsulation improves the performance of liver cell therapies and addresses major challenges in cell transplantation.
The partnership combines AI-powered protein manufacturing with advanced drug delivery technologies to accelerate biologic drug development.
Research shows that PVA hydrogel microencapsulation improves liver cell function over traditional alginate, supporting advanced cell therapies.
An overview of hydrogel-based delivery systems, their chemistry, crosslinking methods, and impact on cell therapy success.
Development of hydrogel microspheres for sustained delivery of stem cells and therapeutics in joint repair.